TGFB1 and lymphedema: Transgenic mice that expressed a dominant‐negative TGF‐β‐receptor II (TGF‐βRII) in LECs had significantly increased lymphangiogenesis and lymphatic collateral vessel formation but did not have improvements in tail lymphedema, suggesting that pathological effects of TGF‐β1 in lymphedema are mediated by changes in the ECM or modulation of inflammatory cell infiltration/function rather than anti‐lymphangiogenic effects.